E5501 A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for EXtensive Stage Small Cell Lung Cancer (SCLC); Topotecan Sequenced with Etopside/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide

E5501 A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC); Topotecan Sequenced with Etopside/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide

Note to institutions: Use of these videos for patient education requires approval of your institution's IRB.

Current therapy of extensive-stage small-cell lung cancer needs to be improved. Small cell lung cancer often responds to initial therapy, but then becomes resistant to standard chemotherapies. As a result, the small-cell lung cancer often returns, and does not respond to additional therapy. The purpose of this study is to try to overcome this resistance that small-cell lung cancers often develop to chemotherapy by using a combination of several currently available and active agents (topotecan, cisplatin, and etoposide; or irinotecan cisplatin, and etoposide) to help overcome the resistance. Alternating the agents may help to overcome the way in which cancer cells protect themselves from the effects of the individual chemotherapy agents such as switching from one repair mechanism (topoisomerase 1) to another (topoisomerase 2).

This randomized phase II study will seek to test two similar regimens (topotecan followed by etoposide and cisplatin (PET), and irinotecan plus cisplatin followed by etoposide (PIE). The regimen which you receive will be chosen at random. This study will seek to determine the effect of the sequence of a topoisomerase 1 inhibitor (topotecan or irinotecan) followed by a topoisomerase 2 inhibitor (etoposide) upon the small cell lung tumor, the effect upon the length of the response, and the effect on survival. This study will also seek to determine the type and severity of the side effects of this combination when used for the treatment of extensive-stage small-cell lung cancer.

You can find additional information about lung cancer and its treatment at the following web sites:


ECOG Introduction to ECOG Clinical Trials Guide For Cancer Patients What is a clinical trial? Why participate? Does insurance cover costs? What if I change my mind? How can I join a clinical trial? ECOG's active protocols Patient Information Selenium E5597 GI Studies E4203,E5202,E5204 Melanoma E2603 Prostate CHAARTED E3805 Cancer in Siblings E1Y97 Non-Hodgkins Lymphoma E4402 Breast Cancer PACCT1: TAILORx Informational Videos Trial Summary Results Trial Monitoring ECOG Data Monitoring Committee ECOG Institutions Institutions by state Alphabetical listing Joining ECOG Publications Publications bibliography Announcements TAILORx Webinar Information NCI Press Release: Bevacizumab... Job Openings Future ECOG Meeting Dates Researcher Advocate Partners Investigator Awards NCI-VA Initiative Scales and Criteria ECOG Performance Status Common Toxicity Criteria Cancer Information Breast Cancer Video Colon Cancer Video Cancer Survivor Publications Releasing Results Guidelines Other Cancer Sites ECOG Main Institutions' Sites Other Cooperative Groups Advocates/Support Groups ECOG HOME PAGE ECOG MEMBERS INFORMATION (password required) GLOSSARY SEARCH CONTACT INFORMATION DISCLAIMER			Eastern Cooperative Oncology Group: E5501 A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC); Topotecan Sequenced with Etopside/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide You can learn more about this trial by viewing a short informational video featuring Dr. Joseph Aisner, the principal investigator for this trial: E5501 Real Media Video E5501 Windows Media Video Click here for a list of institutions participating in this trial Note to institutions: Use of these videos for patient education requires approval of your institution's IRB. Current therapy of extensive-stage small-cell lung cancer needs to be improved. Small cell lung cancer often responds to initial therapy, but then becomes resistant to standard chemotherapies. As a result, the small-cell lung cancer often returns, and does not respond to additional therapy. The purpose of this study is to try to overcome this resistance that small-cell lung cancers often develop to chemotherapy by using a combination of several currently available and active agents (topotecan, cisplatin, and etoposide; or irinotecan cisplatin, and etoposide) to help overcome the resistance. Alternating the agents may help to overcome the way in which cancer cells protect themselves from the effects of the individual chemotherapy agents such as switching from one repair mechanism (topoisomerase 1) to another (topoisomerase 2). This randomized phase II study will seek to test two similar regimens (topotecan followed by etoposide and cisplatin (PET), and irinotecan plus cisplatin followed by etoposide (PIE). The regimen which you receive will be chosen at random. This study will seek to determine the effect of the sequence of a topoisomerase 1 inhibitor (topotecan or irinotecan) followed by a topoisomerase 2 inhibitor (etoposide) upon the small cell lung tumor, the effect upon the length of the response, and the effect on survival. This study will also seek to determine the type and severity of the side effects of this combination when used for the treatment of extensive-stage small-cell lung cancer. You can find additional information about lung cancer and its treatment at the following web sites: National Cancer Institute Lung Cancer Information Lung Cancer Alliance Women Against Lung Cancer Lung Cancer Online CancerCare- It's Time To Focus On Lung Cancer Information about cancer clinical trials can be found at: National Cancer Institute Clinical Trials Information CancerTrials Help - Coalition of Cancer Cooperative Groups

Eastern Cooperative Oncology Group:

E5501 A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC); Topotecan Sequenced with Etopside/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide